Transmedics Group Inc

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TransMedics reports stellar Q4 earnings, eyes growth amid operational challenges

TransMedics Group Inc delivered strong financial performance in Q4 2022, driven by robust revenue growth and strategic investments in infrastructure.
While facing margin pressure and operational challenges, the company's focus on innovation and expansion positions it well for future growth and market leadership.
With a clear roadmap for 2023 and a solid cash position, TransMedics is poised to navigate challenges, capitalize on opportunities, and drive sustainable value creation.

Transmedics reports stellar Q1 results, anticipates growth challenges ahead

Transmedics Group Inc (TMDX) delivered strong financial performance in Q1 2023, driven by the success of the TransMedics NOP and consistent growth in liver and heart cases. Despite facing operational challenges and increased expenses, the company remains optimistic about its growth prospects and revenue guidance for 2023. Strategic focus on product availability and infrastructure expansion bodes well for future success.

TransMedics reports record Q2 revenue, eyes transplant logistics expansion

TransMedics Group Inc's Q2 earnings call highlighted robust performance, strategic acquisitions, and ambitious growth targets, underpinning their market position.
While facing challenges in profitability and operational timelines, the company's focus on enhancing logistics and expanding revenue streams signals a promising trajectory.
Investors should monitor TransMedics' execution of growth plans, including the aviation fleet expansion and next-gen lung system integration, for future value creation.

TransMedics reports stellar Q3 results, eyes expansion and efficiency

TransMedics Group Inc's Q3 earnings call highlighted exceptional revenue growth, operational achievements, and strategic acquisitions, positioning the company for continued success.
The company's focus on revenue diversification, operational efficiency, and innovation underscores its commitment to driving growth and improving patient outcomes.
Despite challenges in growth analysis and program limitations, TransMedics remains optimistic about future opportunities and is poised to capitalize on market trends.

Transmedics Group reports robust earnings, eyes growth in transplant services

Transmedics Group Inc (TMDX) delivered strong financial results in Q4 and full-year 2023, showcasing revenue growth and operational profitability, despite margin pressures.
The company's focus on expanding transplant logistics services, addressing concerns, and presenting data analysis at conferences highlights its commitment to growth and innovation.
With strategic initiatives planned for 2024, TransMedics aims to drive market share in heart, liver, and lung transplants, capitalize on growth opportunities, and enhance operational efficiency for sustained success.
Confidence in providing cost-effective transplant logistics and plans for equal contribution from all three organs position TransMedics for future growth and market leadership in the transplant industry.

TransMedics reports robust Q1 earnings, eyes global expansion and innovation

TransMedics Group Inc (TMDX) delivered strong Q1 2024 results, with notable revenue growth and margin improvement, setting the stage for continued expansion and innovation in the transplant industry.
The company's strategic focus on next-gen technology platforms, new clinical programs, and international market expansion positions it well for sustained growth and leadership in the sector.
While facing challenges in margin improvement and market acceptance, TransMedics has the opportunity to leverage its strengths in product innovation and global appeal to drive future success.

Transmedics Group Inc (TMDX) excels in Q2, eyes clinical program growth

Transmedics Group Inc delivered a stellar performance in Q2 2024, marked by robust revenue growth, operational profitability, and positive free cash flow.
The company's strategic initiatives to expand the aviation fleet, launch new clinical programs, and raise revenue guidance demonstrate a focus on innovation and growth.
While facing challenges in program launches and market competition, Transmedics remains well-equipped to leverage opportunities for market expansion and sustained success.

Transmedics reports robust Q3 performance amidst market challenges

Transmedics Group Inc delivered strong financial results in Q3 2024, driven by robust U.S. sales growth and strategic investments in infrastructure and technology.
While facing challenges with declining transplant volumes and margin pressures, the company remains focused on long-term growth initiatives and maintaining operational efficiency.
Opportunities lie in optimizing international sales, exploring new growth avenues, and leveraging innovative technologies to drive future revenue and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TransMedics came in with another solid quarterly performance with upside in revenue versus consensus. The company is at an inflection point posting a record quarter in terms of sales and gross margin of 70%.

TransMedics Is A Buy Following Q2 FY22 Earnings Upside

Start Time: 16:30 January 1, 0000 5:16 PM ET TransMedics Group, Inc. (NASDAQ:TMDX ) Q2 2022 Earnings Conference Call August 01, 2022, 16:30 PM ET Company Participants Waleed Hassanein - President and CEO Stephen Gordon - CFO Brian Johnston - Gilmartin Group Conference Call Participants Bill Plovanic - Canaccord Genuity Calvin Chu - Morgan Stanley Josh Jennings - Cowen Suraj Kalia - Oppenheimer Allen Gong - JPMorgan Operator Good afternoon, and welcome to TransMedics Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q2 2022 Results - Earnings Call Transcript

Accelerated Commercial Momentum to Achieve Net Revenue of $20.5 million 2022 Revenue Guidance Range Raised to $67 million to $75 million ANDOVER, Mass. , Aug. 1, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2022.

TransMedics Reports Second Quarter 2022 Financial Results

ANDOVER, Mass. , July 26, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference at the InterContinental Boston Hotel.

TransMedics to Present at the Canaccord Genuity 42nd Annual Growth Conference

ANDOVER, Mass. , July 18, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter of 2022 after market close on Monday, August 1, 2022.

TransMedics to Report Second Quarter 2022 Financial Results on August 1, 2022

Veru

Vertex Pharmaceuticals

Have these scorching-hot stocks peaked, or could there still be more gains ahead for investors who buy today?

Bear Market Winners: 3 Healthcare Stocks That Have Soared More Than 30% This Year

Doximity

Intellia Therapeutics

Here's why our roundtable likes Intellia Therapeutics, Doximity, and TransMedics.

Up 1,000% in 5 Years? Here Are 3 Stocks That Can Run That High

TransMedics has started 2022 with great operating momentum. Strong results have resulted in shares recovering after a big selloff early this year.

TransMedics - Impressive Transformation

TransMedics Group Inc (NASDAQ: TMDX) shares got a massive boost after better than expected Q1 earnings and 2022 guidance. The company posted an EPS loss of $(0.38) in line with expectations and higher than $(0.29) a year ago despite more than doubling its sales from Q1 FY21.

TransMedics Stock Skyrockets On Increased 2022 Guidance

Transmedics Group, Inc. (NASDAQ:TMDX ) Q1 2022 Earnings Conference Call May 3, 2022 5:00 PM ET Company Participants Brian Johnston - Gilmartin Group Waleed Hassanein - President and CEO Stephen Gordon - CFO Conference Call Participants Bill Plovanic - Canaccord Genuity Cecilia Furlong - Morgan Stanley Josh Jennings - Cowen Allen Gong - JPMorgan Mike Ott - Oppenheimer Operator Good afternoon and welcome to TransMedics First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Transmedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q1 2022 Earnings Call Transcript

ANDOVER, Mass. , May 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2022.

TransMedics Reports First Quarter 2022 Financial Results

ANDOVER, Mass. , April 28, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its OCS™ Heart System for use with organs from donors after circulatory death (DCD).

TransMedics Receives FDA PMA Approval of OCS™ DCD Heart Indication

ANDOVER, Mass. , April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter of 2022 after market close on Tuesday, May 3, 2022.

TransMedics to Report First Quarter 2022 Financial Results on May 3, 2022

ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that new clinical data from its OCS™ Heart and OCS™ Lung clinical trials will be presented at the upcoming International Society of Heart and Lung Transplantation (ISHLT) 2022 Annual Meeting taking place April 27-30, 2022 in Boston, MA.

TransMedics Announces the Presentation of New OCS™ Heart and OCS™ Lung Clinical Data at the International Society of Heart and Lung Transplantation 2022 Annual Meeting

TransMedics (TMDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

TransMedics (TMDX) Soars 9.9%: Is Further Upside Left in the Stock?

ANDOVER, Mass. , March 1, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming Oppenheimer 32nd Annual Healthcare Conference.

TransMedics to Present at the Oppenheimer's 32nd Annual Healthcare Conference

Transmedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q4 2021 Results - Earnings Call Transcript

ANDOVER, Mass., Feb. 23, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2021.

TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results

ANDOVER, Mass., Feb. 22, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming Cowen 42nd Annual Healthcare Conference.

TransMedics to Present at the Cowen 42nd Annual Healthcare Conference

ANDOVER, Mass., Feb. 9, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23, 2022.

TransMedics to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

ANDOVER, Mass., Jan. 5, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the publication of OCS™ Liver PROTECT Trial Results in JAMA Surgery, a member of the Journal of the American Medical Association (JAMA) Network.

TransMedics Announces Publication of OCS™ Liver PROTECT Trial Results in JAMA Surgery

ANDOVER, Mass. , Dec. 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming 40th Annual J.P.

TransMedics to Present at the 40th Annual J.P. Morgan Healthcare Conference

TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q3 2021 Results - Earnings Call Transcript

TransMedics (TMDX) delivered earnings and revenue surprises of -46.88% and -30.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

TransMedics (TMDX) Reports Q3 Loss, Lags Revenue Estimates

ANDOVER, Mass., Nov. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2021.

News for Transmedics Group Inc Stock (TMDX)